Presentation is loading. Please wait.

Presentation is loading. Please wait.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Published byВиктория Тимковская Modified over 5 years ago

Similar presentations

Presentation on theme: "The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS."— Presentation transcript:

1 The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS. Conventionally treated diabetic subjects received diet plus exercise therapy (113,114). The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS. Conventionally treated diabetic subjects received diet plus exercise therapy (113,114). Ralph A. DeFronzo et al. Dia Care 2013;36:S127-S138 ©2013 by American Diabetes Association

Download ppt "The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS."

Similar presentations

Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:3427-3434.

Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues

Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose- Ranging.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
From: Pharmacologic Therapy for Type 2 Diabetes Mellitus

From: Pharmacologic Therapy for Type 2 Diabetes Mellitus
From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.
Placebo Metformin ***p < vs placebo

Placebo Metformin ***p < vs placebo
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 4 Effect of dapagliflozin on HbA1c and body weight

Figure 4 Effect of dapagliflozin on HbA1c and body weight
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.
Dandan Wang et al. BTS 2018;3:350-362 Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Similar presentations

Ads by Google